What we are studying
The purpose of this study is to test the safety, tolerability and effectiveness (how well the drug works), of the combination of two investigational drugs called nivolumab and ipilimumab in subjects with non-small cell lung cancer (NSCLC).
Nivolumab and ipilimumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab (Opdivo ™) has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of metastatic melanoma (a type of skin cancer), and specific types of previously treated advanced lung and kidney cancers. Ipilimumab (Yervoy™) is approved by the FDA, EMA and other health authorities for the treatment of metastatic melanoma.
The effectiveness will be determined by seeing if treatment with nivolumab and ipilimumab increases the chance you will have a positive response, improves your chances of survival and delays the worsening of your cancer (called progression).